TrialThe New England journal of medicine2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Nitin Jain et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
268 papers cite itlatest 60 shown
this paperpooled ittrialcites it